Consistent with this, HSP90 inhibition decreases activity of multiple survival/metabolic pathways, is toxic to a majority of DLBCL cells and synergizes with inhibitors of certain HSP90 client proteins [16, 20, 21]. This evidence concerns the gene HSP90AB1 and diffuse large B-cell lymphoma.